rotavirus vaccines
Recently Published Documents


TOTAL DOCUMENTS

497
(FIVE YEARS 112)

H-INDEX

47
(FIVE YEARS 7)

Author(s):  
Qassim Mahdi Mutlak ◽  
Manal Khalid Abdulridha ◽  
Laith M Abbas Al-Huseini

Rotaviruses, a major cause of gastroenteritis in children worldwide accounts for around half a million deaths annually. Vaccine against the virus has been recommended by the WHO to be involved in the national immunization program.To evaluate the genetic characterization of rotavirus among children with acute gastroenteritis in Babylon province is warranted. Children complained of diarrhea with rotavirus infection detected in their stool were involved in the study. The age range was 10 months to 60 months and with retrogradechecking of rotavirus vaccine history. Rotavirus genotypes were detected by reverse transcription-polymerase chain reaction (RT-PCR).A total number of 40 children with rotavirus gastroenteritis were used to examine the rotavirus genotyping distribution. The prevalent genotypes were found to be G1, G9, and G2. No significant difference in the distribution of the length of diarrhea according to genotype. Vaccinated children exhibited significantly higher percentage of G2 while G1 and G9 were presented more considerably in not vaccinated children.We detected a variety of rotavirus strains includingthe major global genotypes.Obviously, rotavirus strains are continuing to vary in Iraq. The vaccination changes the genotype prevalence and this situation may create challenges to the effectiveness of rotavirus vaccines and planning for future polices.   Keywords: Rotavirus, Vaccine, Genotype.


Vaccine ◽  
2021 ◽  
Author(s):  
Jessica Price ◽  
Jessica Mooney ◽  
Carolyn Bain ◽  
John Tanko Bawa ◽  
Nikki Gurley ◽  
...  

BMJ Open ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. e052381
Author(s):  
Oluwasegun Jko Ogundele ◽  
Shaza Fadel ◽  
Paula Braitstein ◽  
Erica Di Ruggiero

IntroductionSustainable financing of immunisation programmes is an important step towards universal coverage of life-saving vaccines. Yet, financing mechanisms for health programmes could have consequences on the design of universal approaches to immunisation coverage. Effective implementation of immunisation interventions necessitates investigating the roles of institutions and power on interventions. This review aims to understand how sustainable financing and equitable immunisation are conceptualised by health actors like Gavi, and government-related entities across low-income and middle-income countries (LMICs) and how financing mechanisms can affect universal coverage of vaccines.Methods and analysisThis study protocol outline a scoping review of the peer-reviewed and the grey literature, using established methodological framework for scoping review. Literature will be identified through a comprehensive search of multiple databases and grey literature. All peer-reviewed implementation research studies from the year 2002 addressing financing and universal coverage of immunisation programmes for the pneumococcal conjugated vaccine and rotavirus vaccines immunisation interventions will be included and grey literature published in/after the year 2015. For the study scope, population, concept and context are defined: Population as international and national health stakeholders financing immunisation programmes; Concept as implementation research on pneumococcal conjugate and rotavirus vaccination interventions; and Context as LMICs. Findings will be quantitatively summarised to provide an overview and narratively synthesised and analysed. Studies that do not use implementation research approaches, frameworks or models will be excluded.Ethics and disseminationEthics approval is not required for this scoping review. Findings and recommendations will be presented to implementation researchers and health stakeholders.


2021 ◽  
Author(s):  
Sultan Mahmood

Rotavirus is a double-stranded RNA virus that causes vomiting and diarrhea among children under 5 years. The main cause of mortality from rotavirus gastroenteritis (RVGE) is dehydration if not corrected appropriately with oral rehydration salts (ORS). Though the prevalence of RVGE is similar across countries and socio-economic groups, the higher mortality in Sub-Saharan Africa and South Asia is presumably due to poor awareness and poor health system responsiveness rather than poor hygiene. Enzyme immunoassays are the most commonly used tools for diagnosis of RVGE from stool samples. ORS and zinc remain the mainstay of treatment. Water, sanitation and hygiene measures did not appear to be very effective leaving vaccination among young children as the primary means of prevention. 4 WHO prequalified live attenuated, oral vaccines are available with different efficacy in high- versus low-mortality countries. There is a high degree of protection in countries with low RV mortality, and lower protection in countries with high RV morbidity and more fatalities. Rotavirus vaccines were associated with intussusception, though larger trials failed to establish increased risk in vaccinated groups compared to placebo recipients.


2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S676-S676
Author(s):  
Jordan Cates ◽  
Avnika Amin ◽  
Jacqueline Tate ◽  
Ben Lopman ◽  
Umesh D Parashar

Abstract Background Rotavirus causes 215,000 deaths from severe childhood diarrhea annually. Two rotavirus vaccines – a monovalent vaccine containing a single rotavirus strain (RV1) and a pentavalent vaccine containing 5 rotavirus strains (RV5) – are used in routine immunization programs of nearly 100 countries. Concerns exist that rotavirus vaccines may be less effective against rotavirus strains not contained in the vaccines which could subsequently cause selective pressure and strain replacement. We estimated the vaccine effectiveness (VE) of RV1 and RV5 against vaccine (homotypic) and non-vaccine (partially and fully heterotypic) strains. Methods After conducting a systematic review, we meta-analyzed 31 case-control studies (N=27,293) conducted between 2006 and 2020 using a random-effect regression model. Results In high-income countries, RV1 VE was 10% lower against partially heterotypic (p-value=0.04) and fully heterotypic (p-value=0.10) compared to homotypic strains (homotypic VE: 90% [95% CI: 82, 94]; partially heterotypic VE: 79% [95% CI: 71, 85]; fully heterotypic VE: 80% [95% CI: 65, 88]; Figure 1). In middle-income countries, RV1 VE was 14 to 16% lower against partially heterotypic (p-value=0.06) and fully heterotypic (p-value=0.04) compared to homotypic strains (homotypic VE: 81% [95% CI: 69, 88]; partially heterotypic VE: 67% [95% CI: 54, 76]; fully heterotypic VE: 65% [95% CI: 52, 75]; Figure 1). Strain-specific RV5 VE differences were less pronounced (Figure 2). Limited data were available from low-income countries. Figure 1. Vaccine effectiveness by country income level and strain type, for RV1. Figure 2. Vaccine effectiveness by country income level and strain type, for RV5. Conclusion Vaccine effectiveness of RV1 and RV5 was somewhat lower VE against non-vaccine than vaccine strains. Ongoing surveillance is crucial to continue long-term monitoring for strain replacement, particularly in low-income settings where data are limited. Disclosures All Authors: No reported disclosures


Author(s):  
Michael Haber ◽  
Jacqueline E. Tate ◽  
Benjamin A. Lopman ◽  
Wenrui Qi ◽  
Kylie E. C. Ainslie ◽  
...  

Author(s):  
Ceren Simsek ◽  
Mandy Bloemen ◽  
Daan Jansen ◽  
Leen Beller ◽  
Patrick Descheemaeker ◽  
...  

Despite the global use of rotavirus vaccines, vaccine breakthrough cases remain a pediatric health problem. In this study, we investigated suspected rotavirus vaccine breakthrough cases using next-generation sequencing (NGS) based viral metagenomics (n=102) and a panel of semi-quantitative reverse transcription PCR (RT-qPCR) (n=92) targeting known enteric pathogens. Overall, we identified co-infections in 80% of the cases. Enteropathogens such as Adenovirus (32%), Enterovirus (15%), diarrheagenic Escherichia coli (1-14%), Astrovirus (10%), Blastocystis spp. (10%), Parechovirus (9%), Norovirus (9%), Clostridium difficile (9%), Dientamoeba fragilis (9%), Sapovirus (8%), Campylobacter jejuni (4%) and Giardia lamblia (4%) were detected. Except for a few reassortant rotavirus strains, unusual genotypes or genotype combinations were not present. However, in addition to well-known enteric viruses, divergent variants of enteroviruses and non-classic astroviruses were identified using NGS. We estimated that in 31.5% of the patients, rotavirus was likely not the cause of gastroenteritis and in 14.1% of the patients, it contributed together with another pathogen(s) to disease. The remaining 54.4% of the patients likely had a ‘true vaccine breakthrough infection’. The high prevalence of alternative enteropathogens in the suspected rotavirus vaccine breakthrough cases suggests that gastroenteritis is often the result of a co-infection, and the rotavirus vaccine effectiveness might be underestimated in clinical and epidemiological studies.


Author(s):  
Jordan E. Cates ◽  
Jacqueline E. Tate ◽  
Umesh Parashar

2021 ◽  
Vol 12 ◽  
Author(s):  
Susanna Esposito ◽  
Elena Mariotti Zani ◽  
Lisa Torelli ◽  
Sara Scavone ◽  
Maddalena Petraroli ◽  
...  

Type 1 diabetes (T1D) is the most common paediatric endocrine disease, and its frequency has been found to increase worldwide. Similar to all conditions associated with poorly regulated glucose metabolism, T1D carries an increased risk of infection. Consequently, careful compliance by T1D children with schedules officially approved for child immunization is strongly recommended. However, because patients with T1D show persistent and profound limitations in immune function, vaccines may evoke a less efficient immune response, with corresponding lower protection. Moreover, T1D is an autoimmune condition that develops in genetically susceptible individuals and some data regarding T1D triggering factors appear to indicate that infections, mainly those due to viruses, play a major role. Accordingly, the use of viral live attenuated vaccines is being debated. In this narrative review, we discussed the most effective and safe use of vaccines in patients at risk of or with overt T1D. Literature analysis showed that several problems related to the use of vaccines in children with T1D have not been completely resolved. There are few studies regarding the immunogenicity and efficacy of vaccines in T1D children, and the need for different immunization schedules has not been precisely established. Fortunately, the previous presumed relationship between vaccine administration and T1D appears to have been debunked, though some doubts regarding rotavirus vaccines remain. Further studies are needed to completely resolve the problems related to vaccine administration in T1D patients. In the meantime, the use of vaccines remains extensively recommended in children with this disease.


PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0255436
Author(s):  
Marta Diez Valcarce ◽  
Anita K. Kambhampati ◽  
Laura E. Calderwood ◽  
Aron J. Hall ◽  
Sara A. Mirza ◽  
...  

Acute gastroenteritis (AGE), characterized by diarrhea and vomiting, is an important cause of global mortality, accounting for 9% of all deaths in children under five years of age. Since the reduction of rotavirus in countries that have included rotavirus vaccines in their national immunization programs, other viruses such as norovirus and sapovirus have emerged as more common causes of AGE. Due to widespread use of real-time RT-PCR testing, sapovirus has been increasingly reported as the etiologic agent in both AGE outbreaks and sporadic AGE cases. We aimed to assess the role of sapovirus as a cause of endemic AGE worldwide by conducting a systematic review of published studies that used molecular diagnostics to assess the prevalence of sapovirus among individuals with AGE symptoms. Of 106 articles included, the pooled sapovirus prevalence was 3.4%, with highest prevalence among children <5 years of age (4.4%) and among individuals in community settings (7.1%). Compared to studies that used conventional RT-PCR, RT-qPCR assays had a higher pooled prevalence (5.6%). Among individuals without AGE symptoms, the pooled sapovirus prevalence was 2.7%. These results highlight the relative contribution of sapovirus to cases of AGE, especially in community settings and among children <5 years of age.


Sign in / Sign up

Export Citation Format

Share Document